A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

Clinical Trial
Study Details
Enrollment
6
Interventions
Description

Tablets and capsules which contain GBT021601 drug substance

Name
GBT021601
Type
Drug
Phase
Phase 1
Status
COMPLETED
Study ID #
NCT04983264
Study Type
Interventional
Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK), and pharmacodynamics (i.e., how the body absorbs, distributes, breaks down, and excretes) of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in participants with SCD, following single and multiple ascending doses.

Study Overview
Conditions
Sickle Cell Disease
Description

This is an open-label intrapatient single dose followed by a multiple dose escalation study in at least six (6) participants with SCD.

Contacts and Locations
Locations
Facility

Advanced Pharma CR, LLC
Miami, Florida 33147
United States

GeoPoint
25.77427, -80.19366
Facility

Visionaries Clinical Research LLC
Atlanta, Georgia 30329
United States

GeoPoint
33.749, -84.38798
Facility

Children's Healthcare of Atlanta AFLAC Center
Atlanta, Georgia 30342
United States

GeoPoint
33.749, -84.38798